Denmark-based Novo Nordisk, which makes Ozempic, Rybelsus and Wegovy
Potential Risk Areas Frequently Cited by Researchers Researchers commonly identify several areas where more investigation is needed: Long-term tissue remodeling effects Chronic exposure risks Systemic inflammatory responses Vascular or microcirculatory impact Interactions with existing injuries or conditions Organ-specific accumulation or clearance These represent uncertainties, not confirmed hazards
#CardiovascularDisease #PeripheralArteryDisease #Lipidology #PreventiveCardiology #DigitalHealth #MedTech To view or add a comment, sign in Researchers found that follistatin (FST) protects against atherosclerosis by increasing fat burning, improving mitochondrial function, reducing inflammation, stabilizing arterial plaques, and enhancing lipid metabolism, making it a promising therapeutic target for cardiovascular disease
View Full Study [Antioxidative and detoxifying effects of analogues of delta-sleep inducing peptide (DSIP)]
FGF21 is an endocrine signal of protein restriction
10 mL final volume: 1 mg/mL, 100 mcg per verified 0.10 mL spray, and 100 nominal sprays